Morpholino-Mediated Isoform Modulation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) Reduces Colon Cancer Xenograft Growth

Lessons learned from vivo-morpholinos: How to avoid vivo-morpholino toxicity

(2016) David P. Ferguson et al.   BIOTECHNIQUES

Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer

(2015) Gerald S. Falchook et al.   Oncotarget

The Effect of Bevacizumab on Human Malignant Melanoma Cells with Functional VEGF/VEGFR2 Autocrine and Intracrine Signaling Loops

(2015) Una Adamcic et al.   NEOPLASIA

A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors

(2014) Amita Patnaik et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Blocking autocrine VEGF signaling by sunitinib, an anti-cancer drug, promotes embryonic stem cell self-renewal and somatic cell reprogramming

(2014) Guofang Chen et al.   CELL RESEARCH

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma

(2014) Thomas J. Kaley et al.   NEURO-ONCOLOGY

Antiangiogenic cancer drug sunitinib exhibits unexpected proangiogenic effects on endothelial cells

(2014) Kerri-Ann Norton et al.   OncoTargets and Therapy

Bevacizumab Combination Therapy: A Review of its Use in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

(2013) Sohita Dhillon   BIODRUGS

Pazopanib exposure decreases as a result of an ifosfamide-dependent drug–drug interaction: results of a phase I study

(2013) P Hamberg et al.   BRITISH JOURNAL OF CANCER

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer

(2013) H Chen et al.   BRITISH JOURNAL OF CANCER

Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O6-methylguanine methyltransferase-methylated gliomas

(2013) M. Czabanka et al.   EUROPEAN JOURNAL OF CANCER

A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex – Medicinal chemistry consequences of a TKs analysis

(2013) Lucia Lintnerová et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Update on bevacizumab and other angiogenesis inhibitors for brain cancer

(2013) Mikael L Rinne et al.   EXPERT OPINION ON EMERGING DRUGS

Cadherin-12 contributes to tumorigenicity in colorectal cancer by promoting migration, invasion, adhersion and angiogenesis

(2013) Jingkun Zhao et al.   Journal of Translational Medicine

Phase III Trials of Standard Chemotherapy with or without Bevacizumab for Ovarian Cancer: A Meta-Analysis

(2013) Mingyi Zhou et al.   PLoS One

Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial

(2013) Benjamin M. Ellingson et al.   RADIOLOGY

Role of bevacizumab in colorectal cancer growth and its adverse effects: A review

(2013) Efstathios T Pavlidis   WORLD JOURNAL OF GASTROENTEROLOGY

Modeling Efficacy of Bevacizumab Treatment for Metastatic Colon Cancer

(2013) Rezwan Islam et al.   Journal of Cancer

Effect of cediranib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in a mouse model of choroidal neovascularization

(2012) Seungbum Kang et al.   CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: a Proposed Model for Bevacizumab Resistance

(2012) Arne R.M. van der Bilt et al.   CURRENT PHARMACEUTICAL DESIGN

Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer

(2012) Grzegorz Korpanty et al.   CURRENT PHARMACEUTICAL DESIGN

Deguelin, an Akt Inhibitor, Down-Regulates NF-κB Signaling and Induces Apoptosis in Colon Cancer Cells and Inhibits Tumor Growth in Mice

(2012) Hyoun Woo Kang et al.   DIGESTIVE DISEASES AND SCIENCES

Dual suppression of hemangiogenesis and lymphangiogenesis by splice-shifting morpholinos targeting vascular endothelial growth factor receptor 2 (KDR)

(2012) Hironori Uehara et al.   FASEB JOURNAL

β-Catenin Regulates Deiodinase Levels and Thyroid Hormone Signaling in Colon Cancer Cells

(2012) Monica Dentice et al.   GASTROENTEROLOGY

Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts

(2012) SHAN CHEN et al.   ONCOLOGY REPORTS

Morpholino-Mediated Increase in Soluble Flt-1 Expression Results in Decreased Ocular and Tumor Neovascularization

(2012) Leah A. Owen et al.   PLoS One

Hypoxia down-regulates sFlt-1 (sVEGFR-1) expression in human microvascular endothelial cells by a mechanism involving mRNA alternative processing

(2011) Takayuki Ikeda et al.   BIOCHEMICAL JOURNAL

Vascular Endothelial Growth Factor (VEGF), VEGF Receptors and Their Inhibitors for Antiangiogenic Tumor Therapy

(2011) Satoru Takahashi   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis

(2011) Masabumi Shibuya   BMB Reports

Isoliquiritigenin from licorice root suppressed neovascularisation in experimental ocular angiogenesis models

(2011) V. Jhanji et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Induction of Antagonistic Soluble Decoy Receptor Tyrosine Kinases by Intronic PolyA Activation

(2011) Sandra Vorlová et al.   MOLECULAR CELL

RNAi-mediated inhibition of PDGF-D leads to decreased cell growth, invasion and angiogenesis in the SGC-7901 gastric cancer xenograft model

(2010) Lin Zhao et al.   CANCER BIOLOGY & THERAPY

Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers

(2010) N. R. Smith et al.   CLINICAL CANCER RESEARCH

Functional Rescue of Dystrophin-deficient mdx Mice by a Chimeric Peptide-PMO

(2010) HaiFang Yin et al.   MOLECULAR THERAPY

Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth

(2009) Romulo J C Albuquerque et al.   NATURE MEDICINE

VEGF-A Stimulates ADAM17-Dependent Shedding of VEGFR2 and Crosstalk Between VEGFR2 and ERK Signaling

(2008) Steven Swendeman et al.   CIRCULATION RESEARCH

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE